Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib 4/2 vs 2/1 Schedule in Metastatic RCC
NCT00570882Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Oct 2007
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sunitinib in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by Asan Medical Center. Primary endpoint: Treatment Failure Rate at 12 months. Started Oct 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT00570882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00570882.